Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Vladimir Piotrovsky"'
Autor:
Juan Jose Perez-Ruixo, Monique A. Franc, Stephan Francke, Vladimir Piotrovsky, Peter Zannikos, Vural Ozdemir
Publikováno v:
Cancer Chemotherapy and Pharmacology. 58:681-691
Objective: Evaluate the effect of CYP2D6 genotype on the pharmacokinetics of tipifarnib. Methods: A total of 268 subjects included in six clinical trials were treated orally with tablet formulation of tipifarnib, as a single dose or as multiple b.i.d
Autor:
William J. Jusko, Wojciech Krzyzanski, Juan J. Perez-Ruixo, Andrew T. Chow, Hui C. Kimko, Vladimir Piotrovsky
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 32:767-793
Pharmacokinetic/pharmacodynamic (PK/PD) models for hematological drug effects exist that assume that cells are produced by a zero- or first-order process, survive for a specific duration (cell lifespan), and then are lost. Due to the fact that delay
Publikováno v:
Journal of Clinical Pharmacology. 43:514-523
Galantamine is a reversible, competitive inhibitor of acetylcholinesterase and an allosteric modulator of nicotinic acetylcholine receptors. It is cleared by renal and hepatic mechanisms, including metabolism by the CYP 450 2D6 and 3A4 isoenzymes. Th
Autor:
Vladimir Piotrovsky
Publikováno v:
Drugs and the Pharmaceutical Sciences ISBN: 9781574448085
Dose Optimization In Drug Development
Dose Optimization In Drug Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3c11e9b0f67cc3acb80c834e0f955ad
https://doi.org/10.1201/9781420018585.ch7
https://doi.org/10.1201/9781420018585.ch7
Autor:
Vladimir Piotrovsky
Publikováno v:
The AAPS journal. 7(3)
In this review, factors affecting the QT interval and the methods that are currently in use in the analysis of drug effects on the QT interval duration are overviewed with the emphasis on (population) pharmacokinetic-pharmacodynamic (PK-PD) modeling.
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 34(2)
A population model was developed with the aim to simultaneously describe risperidone and 9-hydroxyrisperidone pharmacokinetics; to obtain estimates for pharmacokinetic parameters and associated inter- and intra-individual variability of risperidone a
Publikováno v:
Current medical research and opinion. 21(4)
To demonstrate using pharmacokinetic (PK) modeling and simulation, that the PK that the PK parameters for drug exposure with galantamine parameters for drug exposure with galantamine immediate-release (IR) tablet and galantamine extended-release (ER)
Publikováno v:
Journal of Pharmacokinetics & Pharmacodynamics; Apr2007, Vol. 34 Issue 2, p183-206, 24p
Autor:
Juan Perez-Ruixo, Hui Kimko, Andrew Chow, Vladimir Piotrovsky, Wojciech Krzyzanski, William Jusko
Publikováno v:
Journal of Pharmacokinetics & Pharmacodynamics; Dec2005, Vol. 32 Issue 5/6, p767-793, 27p